Gulf routes closed: How the Iran-Israel war is stranding Indian travellers and expatriate workers
Indian airlines cancelled 350 flights on March 1, 2026, as US-Israel strikes on Iran triggered airspace closures across West Asia, hitting Air India and IndiGo.
Why Accenture’s acquisition of Aidemy could reshape Japan’s AI reskilling landscape
Discover how Accenture’s acquisition of Aidemy reshapes its AI reskilling strategy and what this means for enterprise digital transformation today.
Roche’s sixth-gen Troponin T test: Can it finally solve the accuracy problem in heart attack diagnosis?
Roche’s sixth-generation Troponin T test delivers new accuracy in heart attack diagnosis. Explore clinical results, adoption hurdles, and investor sentiment.
Inside the Skukum Gold deal: Why Tincorp cashed out and how Blue Jay plans to turn Yukon ounces into growth
Tincorp finalizes the Skukum Gold Project sale to Blue Jay Gold. Learn how the deal reshapes Yukon’s mining outlook and investor sentiment today.
Rare earth refining in America: is the ReElement–POSCO alliance the breakthrough Washington needed?
American Resources (NASDAQ: AREC) and POSCO sign a long-term offtake pact to supply 3,000 MT of rare earths by 2030, reshaping U.S. refining.
Liquid biopsy breakthrough: FDA okays Guardant360 CDx to match patients to Eli Lilly’s Inluriyo
FDA approves Guardant360 CDx as a companion diagnostic for Inluriyo in ESR1-mutated breast cancer. Discover how liquid biopsy is reshaping oncology care today.
AbbVie’s bold gamble: Can Elahere really launch in the UK at full U.S. list price?
AbbVie plans to launch ovarian cancer drug Elahere in UK at U.S. price—testing NICE, NHS, and investor confidence in oncology pricing norms.